Diagnosis dan Tatalaksana Ensefalitis Autoimun Antibodi-Negatif di ICU

Dewi Ramadani Hosen, Osmond Muftilov Pison

Abstract


Ensefalitis autoimun merupakan penyebab utama ensefalitis non-infeksi. Kasus ensefalitis autoimun antibodi-negatif yang dicurigai secara klinis sulit dikonfirmasi. Pada kasus ini dihadapkan pasien laki-laki 27 tahun dirawat dengan demam, penurunan kesadaran, kejang. dan perubahan perilaku sejak 1 bulan yang lalu. Gambaran EEG menunjukkan gelombang epileptiform. Pemeriksaan LCS tidak menunjukkan tanda-tanda infeksi. Pencitraan CT-Scan tidak menunjukkan gambaran khas ensefalitis. Pemeriksaan imunologis IgG dan IgM HSV non-reaktif. Pemeriksaan anti-NMDAR didapatkan hasil negatif. Pasien dirawat di ICU dengan ventilasi mekanik, disertai pemberian midazolam dan levitiracetam sebagai sedasi dan pengontrol kejang. Acyclovir diberikan sesuai pedoman tatalaksana ensefalitis selama 10 hari namun tidak menunjukkan perbaikan klinis. Setelah pemberian kortikosteroid, pasien tidak menunjukkan perbaikan neurologis. Pengobatan dilanjutkan dengan rituximab setiap minggu selama 2 minggu. Pada pemberian minggu pertama pasien menunjukkan perbaikan status neurologis dengan pemulihan derajat kesadaran. Laporan kasus ini mempertimbangkan penegakan diagnosis ensefalitis autoimun antibodi-negatif berdasarkan tanda klinis dan setelah menyingkirkan kemungkinan etiologi lain. Rituximab memainkan peran penting dalam mengendalikan efek merugikan dari ensefalitis autoimun. Di samping itu, ensefalitis autoimun mungkin memerlukan tindak lanjut rutin untuk mengevaluasi adanya gejala atau penyakit lain yang dapat mengubah strategi tatalaksana.


Keywords


Antibodi-negatif; ensefalitis autoimun; imunosupresan; rituximab

Full Text:

PDF

References


  1. Pradhan S, Das A, Das A, Mulmuley M. Antibody negative autoimmune encephalitis- does it differ from definite one. Ann Indian Acad Neurol. 2019;22(4):401–8.
  2. Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, Blackburn KM, Turaga S, Binks S, dkk. Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol. 2023;80(1):30–9.
  3. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, dkk. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology. 2016;15(4):391–401.
  4. Lee SK, Lee ST. The Laboratory Diagnosis of autoimmune encephalitis. J Epilepsy Res. 2016;6(2):45–50.
  5. Rhein Bv, Wagner J, Widman G, Malter MP, Elger CE, Helmstaedter C. Suspected antibody negative autoimmune limbic encephalitis: outcome of immunotherapy. Acta Neurol Scand. 2017;135(1):134–41.
  6. Graus F, Escudero D, Oleaga L, Bruna J, Villarejo-Galende A, Ballabriga J, dkk. Syndrome and outcome of antibody-negative limbic encephalitis. Eur J Neurol. 2018;25(8):1011–6.
  7. Shin YW, Lee ST, Park K Il, Jung KH, Jung KY, Lee SK, dkk. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2018;11:1756285617722347.
  8. D’Amico E, Zanghì A, Gastaldi M, Patti F, Zappia M, Franciotta D. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmun Rev. 2019;18(7):665–72.
  9. D’Amico E, Zanghì A, Chisari CG, Fermo S Lo, Toscano S, Arena S, dkk. Effectiveness and safety of rituximab in demyelinating diseases spectrum: An Italian experience. Mult Scler Relat Disord. 2019;27:324–6.
  10. Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, dkk. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47(3):303–27.
  11. Venkatesan A, Tunkel AR, Bloch KC, Lauring AS, Sejvar J, Bitnun A, dkk. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis. 2013;57(8):1114–28.
  12. Venkatesan A, Geocadin RG. Diagnosis and management of acute encephalitis: A practical approach. Neurol Clin Pract. 2014;4(3):206–15.
  13. Baker AM, Yasavolian MA, Arandi NR. Nonconvulsive status epilepticus: overlooked and undertreated. Emerg Medi Pract. 2019;21(10):1–24.
  14. Ellul M, Solomon T. Acute encephalitis -diagnosis and management. Clin Med (Lond). 2018;18(2):155–9.
  15. Britton PN, Eastwood K, Paterson B, Durrheim DN, Dale RC, Cheng AC, dkk. Consensus guidelines for the investigation and management of encephalitis in adults and children in Australia and New Zealand. Intern Med J. 2015;45(5):563–76.
  16. Gurrera RJ. Recognizing psychiatric presentations of anti-NMDA receptor encephalitis in children and adolescents: A synthesis of published reports. Psychiatry Clin Neurosci. 2019;73(5):262–8.
  17. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, dkk. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2)157–6.
  18. Lee WJ, Lee ST, Byun JI, Sunwoo JS, Kim TJ, Lim JA, dkk. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology. 2016;86(18)1683–91.
  19. Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol. 2016;12(1):1–13.
  20. Martin ST, Cardwell SM, Nailor MD, Gabardi S. Hepatitis B reactivation and rituximab: A new boxed warning and considerations for solid organ transplantation. Am J Transplant. 2014;14(4)788–96.




DOI: https://doi.org/10.15851/jap.v12n2.3765

Article Metrics

Abstract view : 458 times
PDF - 168 times



 

This Journal indexed by

                   

           


 
Creative Commons License
JAP is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 



View My Stats